Ayu Life Sciences, a medical devices and cell therapy company based in India, has announced plans to invest AED33 million (USD9 million) in a state-of-the-art manufacturing facility at Jebel Ali Free Zone (Jafza).
Set to be the first of its kind in the region, the 13,500-square-metre site will specialise in next-generation wound care solutions and surgical treatments, addressing rising global demand for sustainable, high-quality healthcare products.
Ayu Life Sciences Steps onto the Global Stage
Dr Rajan Datt, Managing Director of Ayu Life Sciences, expressed enthusiasm about the company’s expansion into Jafza, describing it as a major achievement.
“We eagerly anticipate commencing construction and expanding access to our flagship products—Velgraft, Velvert, and VelNez—across the Middle East and beyond,” he stated.
Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC, commented that Jafza’s infrastructure and connectivity offer an ideal foundation for innovators like Ayu Life Sciences.
“This facility strengthens Dubai’s position as a global hub for healthcare and advanced medical manufacturing,” he said.
The announcement coincides with increasing demand for artificial skin, with the market forecast to grow from USD3.1 billion in 2024 to USD5.3 billion by 2032.
The new facility will be built in two phases, with the first phase expected to launch by late 2025 and full completion by 2027. It will produce Ayu Life’s patented products—Velgraft, Velvert, and VelNez—crafted using eco-friendly and natural materials to minimise environmental impact.
Presently, Ayu Life Sciences exports from Delhi to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East. The firm is also advancing regenerative medicine with new therapies for Type 1 diabetes and nerve injuries.
